Sutro Biopharma, Inc. (STRO) Reports FY Loss of $1.78

Sutro Biopharma, Inc. (NASDAQ: STRO) reported FY EPS of ($1.78). Revenue for the year came in at $153.73 million.

For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Champions Oncology (CSBR) Tops Q1 EPS by 6c
• Zumiez, Inc. (ZUMZ) Misses Q2 EPS by 6c, Misses on Revenue; Offers Q3 Guidance